Status:
COMPLETED
Sirolimus for Retinal Astrocytic Hamartoma
Lead Sponsor:
The Hospital for Sick Children
Conditions:
Retinal Astrocytic Hamartoma
Eligibility:
MALE
15-16 years
Phase:
NA
Brief Summary
A single patient study using intravitreal Sirolimus to treat a patient with multiple retinal astrocytic hamartomas (RAH) of both eyes.
Detailed Description
Retinal astrocytic hamartomas (RAH) are benign tumors of glial cells arising from astrocytes in the nerve-fiber layer of the retina. They are often associated with tuberous sclerosis complex (TSC) and...
Eligibility Criteria
Inclusion
- Single case diagnosed with multiple retinal astrocytic hamartomas (RAH) of both eyes with imminent threat to vision.
Exclusion
Key Trial Info
Start Date :
November 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 22 2024
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04707209
Start Date
November 4 2020
End Date
March 22 2024
Last Update
March 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Hospital for Sick Children
Toronto, Ontario, Canada, M5G1X8